MENU
+Compare
IMUX
Stock ticker: NASDAQ
AS OF
May 12 closing price
Price
$0.99
Change
-$0.02 (-1.98%)
Capitalization
94.54M

IMUX Immunic Forecast, Technical & Fundamental Analysis

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for IMUX with price predictions
May 09, 2025

IMUX's Stochastic Oscillator remains in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for IMUX crossed bullishly above the 50-day moving average on May 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 154 cases where IMUX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for IMUX moved out of overbought territory on April 30, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IMUX as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IMUX turned negative on May 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

IMUX moved below its 50-day moving average on May 06, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMUX broke above its upper Bollinger Band on April 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.131) is normal, around the industry mean (14.689). P/E Ratio (0.000) is within average values for comparable stocks, (63.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.989). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (253.495).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

IMUX is expected to report earnings to fall 11.00% to -22 cents per share on May 12

Immunic IMUX Stock Earnings Reports
Q1'25
Est.
$-0.22
Q4'24
Missed
by $0.01
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.02
Q1'24
Missed
by $0.04
The last earnings report on March 20 showed earnings per share of -25 cents, missing the estimate of -23 cents. With 692.04K shares outstanding, the current market capitalization sits at 94.54M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA318.3820.12
+6.75%
Tesla
AAPL210.7912.52
+6.31%
Apple
SPY582.9918.65
+3.30%
SPDR® S&P 500® ETF
GME28.050.51
+1.85%
GameStop Corp
BTC.X102812.950000-1293.406200
-1.24%
Bitcoin cryptocurrency

IMUX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with ARCT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMUX
1D Price
Change %
IMUX100%
-0.98%
ARCT - IMUX
38%
Loosely correlated
-3.51%
VYGR - IMUX
37%
Loosely correlated
-7.58%
IMNM - IMUX
37%
Loosely correlated
-3.24%
SLDB - IMUX
36%
Loosely correlated
-0.36%
RXRX - IMUX
36%
Loosely correlated
-1.37%
More